Operating in the pharmaceutical distribution sector, Saya Group started pharmaceutical production in Çerkezköy with an investment of 120 million dollars. With Pharmactive, Saya aims to be one of the top 5 generic pharmaceutical companies in Turkey with a turnover of 300 million dollars in 5 years.
The drugs to be produced in the facility, which has a production capacity of 330 million boxes, are planned to be sold to developed and developing markets, including the USA and European Countries. Pharmactive will employ more than 2 people when all phases are completed.
The official opening of the production facility, which will have a total investment cost of 200 million dollars, will take place in October when all stages are completed.
Saying that the facility is among the top 10 facilities in Europe in terms of production capacity, Saya Group Vice Chairman of the Board of Directors, Haluk Sancak, said, "We completed the facility in a very short time, such as 4 years, which should be completed in 5-2 years under normal conditions." Sancak added that with the completion of the second phase of the production facility, which will have a closed area of 80 m2 in total, they will have a production capacity of 2 million boxes of pharmaceuticals.
DESTINATION OF EXPORT TO USA
Emphasizing that Pharmactive attaches great importance to R&D investments, Pharmactive General Manager Köksal Ülgen said, “We are developing generic drugs with high added value in R&D, where we invested 20 million dollars in the first stage to achieve our growth targets. With the second phase, our R&D investment will reach 35 million dollars.”
Stating that they aim to provide approximately 25 percent of their turnover in the medium term through export activities, Ülgen said, “We aim to sell pharmaceuticals to developed and developing markets, including the USA and European countries. We aim to reduce the current account deficit level of the pharmaceutical industry and therefore the Turkish economy.”
Source : Hurriyet